TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06619860: A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Sponsor: Vertex Pharmaceuticals Incorporated · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$9,001,600

Rescue Site Savings

+$5,936,400

Unlock Full NCT06619860 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06619860 Rescue Dossier →